1. Scrip

Positive Atopic Dermatitis Data On Lilly's Newly-Approved Olumiant

Just Received European Green Light For Skin Disorder

 
• By Kevin Grogan

It has gone under the radar that Eli Lilly and Incyte's Olumiant has recently become the first JAK inhibitor to be approved anywhere for atopic dermatitis and the companies have been touting promising long-term data on the therapy as it expands beyond rheumatoid arthritis.  

Scratching
Atopic dermatitis is a potentially lucrative market for Lilly • Source: Shutterstock

Days after Olumiant became the first JAK inhibitor to be approved in Europe for atopic dermatitis,Eli Lilly and Company and partner Incyte Corporation have presented more positive data on the drug for the skin disease and highlighted its potential as a treatment for alopecia.

The US giant gave little fanfare to the European Commission's approval last week for Olumiant (baricitinib) for the treatment of adults with moderate to severe atopic dermatitis who are candidates...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from New Products

More from Scrip

Merus Bispecific Impresses In Head And Neck Cancer

 
• By Andrew McConaghie

Updated Phase II results from petosemtamab have impressed ahead of ASCO, outshining Keytruda monotherapy and its bispecific rival from Bicara.

Zydus To Continue Mirabegron Sales, Looks To World-First Dual Shigella-Typhoid Vaccine

 
• By Vibha Ravi

Zydus expects strong mirabegron sales in FY26 amid US litigation even as it builds a growth pillar in vaccines with a world-first, Gates Foundation-aided dual shigella-typhoid vaccine under development and others on the WHO prequalified list

Challenging Environment For Biopharma Is A Tailwind For Royalty Pharma

 
• By Jessica Merrill

The royalty revenue stream acquirer has around 40 products in its portfolio and expects to generate roughly $3bn this year. Head of R&D and investments Marshall Urist talked about the investment strategy at the RBC Healthcare Conference.